Journals / Şişli Etfal Hastanesi Tıp Bülteni / 2022 / Cilt: 56 - Sayı: 1

Low Vitamin D Status is Not Associated with the Aggressive Pathological Features of Papillary Thyroid Cancer

Pages
132–136
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: According to our results, serum Vit D levels are not associated with the aggressive tumor characteristics of PTC.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: In the present study, we investigated the effects of Vitamin D (vit D) deficiency on aggressiveness of papillary thyroid cancer (PTC).
📊
Key Findings & Data:Methods: Patients with PTC confirmed with pathological examination, whom were operated by a single surgeon between 2012 and 2017, were included in the study.
💡
Conclusion & Impact:Conclusion: According to our results, serum Vit D levels are not associated with the aggressive tumor characteristics of PTC.
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: In the present study, we investigated the effects of Vitamin D (vit D) deficiency on aggressiveness of papillary thyroid cancer (PTC). Methods: Patients with PTC confirmed with pathological examination, whom were operated by a single surgeon between 2012 and 2017, were included in the study. The data of the patients were analyzed retrospectively. Cancers other than PTC, patients with hyperthyroidism and/or using antithyroid drugs were excluded from the study. The patients were classified as four quartiles according to serum Vit D levels; category 1 (23.5 ng/mL). Results: A total of 133 patients (103 female, 30 male) with mean age of 46.4±13.6 (17–82) years were included in the study. There was no significant difference between the categories in terms of preoperative Vit D values according to the evaluated tumor ag- gressiveness characteristics. It was determined that the presence of tumor with a size above 1 cm and T3/4 tumor were not affected by Vit D level. There was no significant difference between Vit D categories regarding the characteristics of aggressiveness such as multicentricity, lymphovascular invasion, central, and lateral metastases. Conclusion: According to our results, serum Vit D levels are not associated with the aggressive tumor characteristics of PTC.

🔖

Cite This Article

Ozguven, B. Y., Aygun, N., Demircioglu, M. K., Demircioglu, Z. G., Uludag, M. (2022). Low Vitamin D Status is Not Associated with the Aggressive Pathological Features of Papillary Thyroid Cancer. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 56 - Sayı: 1, 132–136. https://ajindex.com/articles/594616

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr 2008;88:491S−9S
  2. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 2014;14:342−57
  3. Mondul AM, Weinstein SJ, Layne TM, Albanes D. Vitamin D and cancer risk and mortality: state of the science, gaps, and chal- lenges. Epidemiol Rev 2017;39:28−48
  4. Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet 2016;388:2783−95
  5. Holick MF. The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord 2017;18:153−65
  6. Thacher TD, Clarke BL. Vitamin D insufficiency. Mayo Clin Proc 2011;86:50−60
  7. Binkley N, Dawson-Hughes B, Durazo-Arvizu R, Thamm M, Tian L, Merkel JM, et al. Vitamin D measurement standardization: The way out of the chaos. J Steroid Biochem Mol Biol 2017;173:117−21
  8. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911−30
  9. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Niki- forov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differen- tiated thyroid cancer: The American Thyroid Association Guide- lines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1−133
  10. Göktaş O, Ersoy C, Ercan I, Can FE. Vitamin D status in the adult population of Bursa-Turkey. Eur J Gen Pract 2020;26:156−62
  11. Öncül Börekçi N. Current information on vitamin D deficiency. Jour Turk Fam Phy 2019;10:35−42
  12. Jonklaas J, Danielsen M, Wang H. A pilot study of serum selenium, vitamin D, and thyrotropin concentrations in patients with thy- roid cancer. Thyroid 2013;23:1079−86
  13. Ahn HY, Chung YJ, Park KY, Cho BY. Serum 25-hydroxyvitamin D level does not affect the aggressiveness and prognosis of papil- lary thyroid cancer. Thyroid 2016;26:429−33
  14. Li M, Chen P, Li J, Chu R, Xie D, Wang H. Review: the impacts of cir- culating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2014;99:2327−36
  15. Zhao J, Wang H, Zhang Z, Zhou X, Yao J, Zhang R, et al. Vitamin D deficiency as a risk factor for thyroid cancer: A meta-an